Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk
December 20, 2018 – This is very troubling news for all patients worldwide with diabetes and who are under therapy with drugs out of the DPP-4 class of inhibitors: A very recent population-based epidemiological study indicates that patients under DPP-4 inhibitors …
Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk Read more »